← Human Trials & Peer-Reviewed Studies
Brief Advice, Nicotine Replacement Therapy Sampling, and Active Referral for Expectant Fathers Who Smoke Cigarettes: A Randomized Clinical Trial.
Plain-language guide to PMID 34125135 (2021): randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 1053 participants.
Key Facts
- PMID
- 34125135
- Journal
- JAMA internal medicine
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Luk TT et al. (13 authors)
- DOI
- 10.1001/jamainternmed.2021.2757
- Registered trial
- NCT03671707
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
Pregnancy presents an opportunity to engage expectant fathers in smoking cessation, but evidence from randomized clinical trials is scarce.
Who Took Part
The study group was 1053 participants.
By PubMed's age tags, the people studied were adults, both men and women.
This pragmatic randomized clinical trial in prenatal clinics in 7 public hospitals in Hong Kong proactively recruited and enrolled 1053 participants from October 10, 2018, to February 8, 2020.
These participants were randomized to either the intervention group or the control group.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The primary analyses used an intention-to-treat approach.
The intervention group received brief cessation advice, a 1-week free sample of nicotine replacement therapy (NRT), and active referral to a community-based smoking cessation service.
What Was Measured
Topics PubMed links to this paper include Behavior Therapy, Breath Tests, Carbon Monoxide, Cigarette Smoking, Family Health, Fathers and Interpersonal Relations.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide) in 1053 participants.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (JAMA internal medicine), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.